FDA Approves New Antibiotic

May 31, 2014 13:00 pm

by Eric The Younger · 10 comments

This is kind of a big deal. Over the last couple decades there have been fewer and fewer antibiotics researched and approved by the FDA. Vox has a nifty chart that shows the decline of new approval over the last 30 years. With the rise of drug resistant bacteria, this is indeed a problem. Hopefully there are more antibiotics like this one in the pipeline.

Here are Phil Gingrey and Gene Greene’s thoughts.

Gingrey and Greene applaud FDA approval of first GAIN Act antibiotic

The U.S. Food and Drug Administration (FDA) recently approved the first antibacterial medication aimed at stopping the rapid spread of antibiotic-resistant “Superbugs,” which were previously impervious to available treatments. The new drug, Dalvance (dalbavancin), is the first Qualified Infectious Disease Product (QIDP) to be approved for human consumption under Reps. Phil Gingrey, M.D., and Gene Greene’s Generating Antibiotic Incentives Now Act – a bipartisan effort to defeat the threat of these drug-resistant infections.

Rep. Gingrey: “The GAIN Act has been a great success for the medical community and their patients. The approval of Dalvance is a momentous step in mitigating the risk antibiotic-resistant bacteria poses to patients, and will spur greater investment in future treatments to help fight this ever-increasing public health threat.”

Rep. Greene: “For too long, new drugs have been scarce, while resistant bacteria have become rampant. GAIN was a critical first step in addressing the need for newer and more effective antibiotics and this approval marks the first success of the law. As we celebrate this achievement, we must not abandon our commitment to addressing the anemic antibiotic pipeline and barriers to research, development and innovation of new and better antimicrobials to treat the increasing number of drug-resistant infections.”

Chris Huttman May 31, 2014 at 3:40 pm

Someone who works at the CDC told me the big problem is people get a bug, get a course of antibiotics say a 7 day course, take the first 4, feel better, stop taking the rest and then it comes back and have to move up to a stronger antibiotic, the bug may now be immune to the weaker one (that was working but didn’t get the chance to knock it out).

Eric The Younger June 1, 2014 at 11:24 am

Yep, that’s the biggest contributor to the problem.

Harry June 1, 2014 at 1:29 pm

It’s obviously a losing battle. Evolution will defeat countermeasures, probably sooner than later.

MattMD June 1, 2014 at 11:11 pm

Patient compliance to medication (don’t get me started on psychiatric issues) is a big issue in any treatment but especially with bacteria.

With the fun drugs, there is less of an issue.

Chris Huttman June 2, 2014 at 3:31 pm

It would honestly probably be cheaper to have people take the pill while a nurse watches on Skype (and then compensate the patient some small amount – $5?) than it would be to have to develop new antibiotics.

MattMD June 2, 2014 at 10:02 pm

Microbes are still going to evolve but anything to slow that pace might be good. People could use reminders, that is for sure.

Ellynn June 3, 2014 at 10:06 am

I would love if new antibiotics were developed. Maybe they can find some that won’t kill me or land me in a hopsital for a few days.

Hardly June 1, 2014 at 10:28 pm

Extremely disappointed in Dr. Gingrey! This “momentous antibiotic” is from the very same people screaming about climate change: SCIENTISTS!!! Can’t believe my representative fell for this new hoax!

MattMD June 1, 2014 at 11:14 pm

Lies from the pit of a scanning electron microscope! (Yeah, I know that is from Paul)

Ellynn June 2, 2014 at 10:18 am

For those of you with bad drug reaction histories, this is in the same class as mycin based antibiotics.

Comments on this entry are closed.